<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39338442</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO<sub>2</sub> Requirements.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1767</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms12091767</ELocationID><Abstract><AbstractText>Once a patient has been diagnosed with severe COVID-19 pneumonia, treatment options have limited effectiveness. Opaganib is an oral treatment under investigation being evaluated for treatment of hospitalized patients with severe COVID-19 pneumonia. A randomized, placebo-controlled, double-blind phase 2/3 trial was conducted in 57 sites worldwide from August 2020 to July 2021. Patients received either opaganib (n = 230; 500 mg twice daily) or matching placebo (n = 233) for 14 days. The primary outcome was the proportion of patients no longer requiring supplemental oxygen by day 14. Secondary outcomes included changes in the World Health Organization Ordinal Scale for Clinical Improvement, viral clearance, intubation, and mortality at 28 and 42 days. Pre-specified primary and secondary outcome analyses did not demonstrate statistically significant benefit (except nominally for time to viral clearance). Post-hoc analysis revealed the fraction of inspired oxygen (FIO<sub>2</sub>) at baseline was prognostic for opaganib treatment responsiveness and corresponded to disease severity markers. Patients with FIO<sub>2</sub> levels at or below the median value (≤60%) had better outcomes after opaganib treatment (n = 117) compared to placebo (n = 134). The proportion of patients with ≤60% FIO<sub>2</sub> at baseline that no longer required supplemental oxygen (≥24 h) by day 14 of opaganib treatment increased (76.9% vs. 63.4%; nominal <i>p</i>-value = 0.033). There was a 62.6% reduction in intubation/mechanical ventilation (6.84% vs. 17.91%; nominal <i>p</i>-value = 0.012) and a clinically meaningful 62% reduction in mortality (5.98% vs. 16.7%; nominal <i>p</i>-value = 0.019) by day 42. No new safety concerns were observed. While the primary analyses were not statistically significant, post-hoc analysis suggests opaganib benefit for patients with severe COVID-19 requiring supplemental oxygen with an FIO<sub>2</sub> of ≤60%. Further studies are warranted to prospectively confirm opaganib benefit in this subpopulation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neuenschwander</LastName><ForeName>Fernando Carvalho</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Núcleo de Pesquisa Clínica-Hospital Vera Cruz, Belo Horizonte 30190-130, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnett-Griness</LastName><ForeName>Ofra</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Bioforum Ltd., Ness Ziona 7403636, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piconi</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7058-1048</Identifier><AffiliationInfo><Affiliation>Ospedale A. Manzoni, 23900 Lecco, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maor</LastName><ForeName>Yasmin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7258-3434</Identifier><AffiliationInfo><Affiliation>Infectious Disease Unit, E. Wolfson Medical Center, Holon 58100, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sprinz</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assy</LastName><ForeName>Nimer</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2279-6041</Identifier><AffiliationInfo><Affiliation>Western Galilee Medical Center, Nahariya 221001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khmelnitskiy</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Saint-Petersburg State Budget Healthcare Institution "City Pokrovskaya Hospital", Saint-Petersburg 199106, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomakin</LastName><ForeName>Nikita V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow 121359, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goloshchekin</LastName><ForeName>Boris Mikhailovich</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Saint-Petersburg SBHI City Hospital 15, Saint-Petersburg 197110, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahorecka</LastName><ForeName>Ewelina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Zespół Opieki Zdrowotnej, 59-700 Bolesławiec, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joaquim Westheimer Calvacante</LastName><ForeName>Adilson</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CEMEC-Centro Multidisciplinar de Estudos Clinicos LTDA, São Bernardo do Campo 09715-090, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanova</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>State Budgetary Institution of Ryazan Region "Regional Clinical Hospital", Ryazan 390026, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vladimirovich Zhuravel</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9992-9260</Identifier><AffiliationInfo><Affiliation>N.V. Sklifosovsky Research Institute for Emergency Medicine of Health Department of Moscow, Moscow 129090, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yurevna Trufanova</LastName><ForeName>Galina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>State Budgetary Healthcare Institution of the Tver Region "Regional Clinical Hospital", Tver 170100, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonora</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ospedale Amedeo di Savoia, 10149 Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saffoury</LastName><ForeName>Amer</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nazareth Hospital EMMS, Nazareth 19152, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Ami</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0006-1821-886X</Identifier><AffiliationInfo><Affiliation>Assuta Medical Center Ashdod, Ashdod 7747629, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shvarts</LastName><ForeName>Yury G</ForeName><Initials>YG</Initials><Identifier Source="ORCID">0000-0002-5205-7311</Identifier><AffiliationInfo><Affiliation>Clinical Hospital n.a-S.R. Mirotvortseva SSMU, Saratov 410012, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzardini</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ospedale Luigi Sacco, 20157 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobroza de Mello</LastName><ForeName>Rogerio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital Nossa Senhora da Conceição de Tubarão, Centro de Pesquisas Clínicas do Hospital Nossa Senhora da Conceição, Tubarão 88701-160, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilau</LastName><ForeName>Janaina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital de Clínicas de Passo Fundo, Cento de Pesquisa Clínica, Passo Fundo 99010-260, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klinov</LastName><ForeName>Alexey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Kirovsk Interregional Hospital, Leningrad 187342, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente-Acosta</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9885-3594</Identifier><AffiliationInfo><Affiliation>Hospital ABC, Mexico City 05348, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olegovich Burlaka</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Saint-Petersburg State Budgetary Healthcare Institution "City Aleksandrovskaya Hospital", Saint-Petersburg 193312, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakhtina</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Regional Budgetary Healthcare Institution Murmansk Regional Clinical Hospital, Murmansk 183032, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bar-Meir</LastName><ForeName>Maskit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shaare Zedek Medical Center, Jerusalem 9103102, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolaevich Shishimorov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Neonatology, Institute of Medical and Physiotherapy, Federal State Budgetary Educational Institution of Higher Education Volgograd State Medical University, Volgograd 400087, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oñate-Gutierrez</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro Medico Imbanaco de Cali, Valle del Cauca 760042, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García Rincón</LastName><ForeName>Cristian Iván</ForeName><Initials>CI</Initials><AffiliationInfo><Affiliation>Unidad de Transferencia y Ensayos Clínicos Clinica Universitaria Bolivariana, Medellin 050021, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanovna Martynenko</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Regional State Budgetary Healthcare Institution "City Hospital No. 5, Barnaul", Barnaul 656045, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajjar</LastName><ForeName>Ludhmila Abrahão</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Instituto do Coração do Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Andar 05403-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carolina Nazare de Mendonca Procopio</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Felicio Rosso, Belo Horizonte 30110-934, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Szpital Specjalistyczny im. Gromkowskiego, 51-149 Wrocław, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel Chaves Santiago</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Sociedad de Cirugía de Bogotá Hospital de San José, Bogota 110821, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fronczak</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centrum Onkologii w Lodzi, Oddzial COVID-19, 93-510 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberto Hoffmann Filho</LastName><ForeName>Conrado</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8585-7940</Identifier><AffiliationInfo><Affiliation>Hospital Regional Hans Dieter Schmidt, Joinville 89227-680, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Ziv Medical Center, Safed 13100, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aleksandrovich Martynov</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0117-0613</Identifier><AffiliationInfo><Affiliation>State Budgetary Healthcare Institution of the Tver Region "Regional Clinical Hospital", Ryazan 390026, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chichino</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Azienda Ospedaliera SS, 15121 Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blewaska</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Szpital Rejonowy w Raciborzu, 47-400 Racibórz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wroblewski</LastName><ForeName>Jacek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Szpital Wojewódzki im. Mikołaja Kopernika, 75-581 Koszalin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saul Irizar Santana</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital Civil de Culiacan, Sinaloa 80030, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felipe Ocampo Agudelo</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundacion Hospitalaria San Vicente, Antioquia 050001, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barczyk</LastName><ForeName>Adam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6567-9208</Identifier><AffiliationInfo><Affiliation>Department of Pneumology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lask Gerlach</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>RedHill Biopharma Ltd., Tel-Aviv 6473921, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Eppie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>RedHill Biopharma Ltd., Tel-Aviv 6473921, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bibliowicz</LastName><ForeName>Aida</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0002-5555-6973</Identifier><AffiliationInfo><Affiliation>RedHill Biopharma Ltd., Tel-Aviv 6473921, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fathi</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>RedHill Biopharma Ltd., Tel-Aviv 6473921, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>RedHill Biopharma Ltd., Tel-Aviv 6473921, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raday</LastName><ForeName>Gilead</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>RedHill Biopharma Ltd., Tel-Aviv 6473921, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bioforum Ltd., Ness Ziona 7403636, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehrmann</LastName><ForeName>Clara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0008-6188-6059</Identifier><AffiliationInfo><Affiliation>CEEF Solutions Beaconsfield, Pointe-Claire, QC H9S 4L7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eagle</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>G.E.T. Pharma Consulting, LLC, Lumberville, PA 18933, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben-Yair</LastName><ForeName>Vered Katz</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>RedHill Biopharma Ltd., Tel-Aviv 6473921, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levitt</LastName><ForeName>Mark L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-5141-0451</Identifier><AffiliationInfo><Affiliation>RedHill Biopharma Ltd., Tel-Aviv 6473921, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>RedHill Biopharma, Ltd.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABC294640</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 pneumonia</Keyword><Keyword MajorTopicYN="N">opaganib</Keyword><Keyword MajorTopicYN="N">sphingosine kinase 2</Keyword><Keyword MajorTopicYN="N">trial registration number: NCT04467840</Keyword></KeywordList><CoiStatement>Authors Ofra Barnett-Griness, Rachael lask Gerlach, Eppie Campbell, Aida Bibliowicz, Reza Fathi, Patricia Anderson, Gilead Raday, Vered Katz Ben-Yair, Mark L. Levitt, Clara Fehrmann and Gina Eagle were employed by the companies Bioforum Ltd., RedHill Biopharma Ltd, CEEF Solutions Beaconsfield and G.E.T. Pharma Consulting, LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39338442</ArticleId><ArticleId IdType="pmc">PMC11434591</ArticleId><ArticleId IdType="doi">10.3390/microorganisms12091767</ArticleId><ArticleId IdType="pii">microorganisms12091767</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO COVID-19 Dashboard. World Health Organization; Geneva, Switzerland: 2020.  [(accessed on 15 June 2023)].  Updated Daily. Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>World Health Organization  Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Published 26 November 2021.  [(accessed on 20 July 2022)]; Available online:  www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  Coronavirus (COVID-19): Drugs. Date Last Updated: 29 December 2023.  [(accessed on 5 May 2024)]; Available online:  www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs.</Citation></Reference><Reference><Citation>WHO Solidarity Trial Consortium Repurposed Antiviral Drugs for COVID-19—Interim Who Solidarity Trial Results. N. Engl. J. Med. 2021;384:497–511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>French K.J., Zhuang Y., Maines L.W., Gao P., Wang W., Beljanski V., Upson J.J., Green C.L., Keller S.N., Smith C.D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp. Ther. 2010;333:129–139. doi: 10.1124/jpet.109.163444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.109.163444</ArticleId><ArticleId IdType="pmc">PMC2846016</ArticleId><ArticleId IdType="pubmed">20061445</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid S.P., Tritsch S.R., Kota K., Chiang C.Y., Dong L., Kenny T., Brueggemann E.E., Ward M.D., Cazares L.H., Bavari S. Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex. Emerg. Microbes Infect. 2015;4:e61. doi: 10.1038/emi.2015.61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2015.61</ArticleId><ArticleId IdType="pmc">PMC4631929</ArticleId><ArticleId IdType="pubmed">26576339</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitner E.B., Avraham R., Politi B., Melamed S., Israely T. Elevation in sphingolipid upon SARS-CoV-2 infection: Possible implications for COVID-19 pathology. Life Sci. Alliance. 2021;5:e202101168. doi: 10.26508/lsa.202101168.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202101168</ArticleId><ArticleId IdType="pmc">PMC8605327</ArticleId><ArticleId IdType="pubmed">34764206</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitner E.B., Achdout H., Avraham R., Politi B., Cherry L., Tamir H., Yahalom-Ronen Y., Paran N., Melamed S., Erez N., et al. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus. J. Biol. Chem. 2021;296:100470. doi: 10.1016/j.jbc.2021.100470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100470</ArticleId><ArticleId IdType="pmc">PMC7904475</ArticleId><ArticleId IdType="pubmed">33639165</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C.D., Maines L.W., Keller S.N., Katz Ben-Yair V., Fathi R., Plasse T.F., Levitt M.L. Recent progress in the development of opaganib for the treatment of COVID-19. Drug Des. Devel. Ther. 2022;16:2199–2211. doi: 10.2147/DDDT.S367612.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S367612</ArticleId><ArticleId IdType="pmc">PMC9288228</ArticleId><ArticleId IdType="pubmed">35855741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebenezer D.L., Berdyshev E.V., Bronova I.A., Liu Y., Tiruppathi C., Komarova Y., Benevolenskaya E.V., Suryadevara V., Ha A.W., Harijith A., et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019;74:579–591. doi: 10.1136/thoraxjnl-2018-212378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2018-212378</ArticleId><ArticleId IdType="pmc">PMC6834354</ArticleId><ArticleId IdType="pubmed">30723184</ArticleId></ArticleIdList></Reference><Reference><Citation>Winthrop K.L., Skolnick A.W., Rafiq A.M., Beegle S.H., Suszanski J., Koehne G., Barnett-Griness O., Bibliowicz A., Fathi R., Anderson P., et al. Opaganib in Coronavirus Disease 2019 pneumonia: Results of a Randomized, Rlacebo-Controlled Phase 2a Trial. Open Forum. Infect. Dis. 2022;9:ofac232. doi: 10.1093/ofid/ofac232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac232</ArticleId><ArticleId IdType="pmc">PMC9129144</ArticleId><ArticleId IdType="pubmed">35832268</ArticleId></ArticleIdList></Reference><Reference><Citation>RedHill Biopharma Limited  Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia. clinicaltrials.gov; 2021. Date last updated: 20 July 2023.  [(accessed on 14 June 2023)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04467840.</Citation></Reference><Reference><Citation>Assouline O., Ben-Chetrit E., Helviz Y., Kurd R., Leone M., Einav S. Experimental and Compassionate Drug Use During the First Wave of the COVID-19 Pandemic: A Retrospective Single-Center Study. Adv. Ther. 2021;38:5165–5177. doi: 10.1007/s12325-021-01890-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-021-01890-9</ArticleId><ArticleId IdType="pmc">PMC8381349</ArticleId><ArticleId IdType="pubmed">34424502</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health  Information on COVID-19 Treatment, Prevention and Research.  [(accessed on 15 June 2023)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/</Citation></Reference><Reference><Citation>Salama C., Han J., Yau L., Reiss W.G., Kramer B., Neidhart J.D., Criner G.J., Kaplan-Lewis E., Baden R., Pandit L., et al. Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia. N. Engl. J. Med. 2021;384:20–30. doi: 10.1056/NEJMoa2030340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2030340</ArticleId><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas I.O., Diaz G., Gottlieb R.L., Lobo S.M., Robinson P., Hunter B.D., Cavalcante A.W., Overcash J.S., Hanania N.A., Skarbnik A., et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: A randomized clinical trial. Intensive. Care Med. 2021;47:1258–1270. doi: 10.1007/s00134-021-06507-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06507-x</ArticleId><ArticleId IdType="pmc">PMC8490137</ArticleId><ArticleId IdType="pubmed">34609549</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. doi: 10.1016/S0140-6736(21)00676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration  Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. Date Last Updated: 22 December 2021.  [(accessed on 18 April 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19.</Citation></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martín-Quirós A., Caraco Y., Williams-Diaz A., Brown M.L., et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.K., Singh A., Singh R., Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab. Syndr. 2021;15:102329. doi: 10.1016/j.dsx.2021.102329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102329</ArticleId><ArticleId IdType="pmc">PMC8556684</ArticleId><ArticleId IdType="pubmed">34742052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>